Sign inJoin waitlistJoin the waitlist

Marcio Malogolowkin

Chief, Division of Pediatric Hematology-Oncology · University of California Davis Health

Credentials: · · · ·

History

Division of Pediatric Hematology-Oncology · University of California Davis Health
Present
Division of Pediatric Oncology · University of California Davis Health
Present
University of California Davis Health
Present

Pediatrics
Children's Hospital Los Angeles
1991–1992
Pediatric Hematology Oncology
Children's Hospital Los Angeles
1986–1989
Faculty of Medicine at the Federal University of Rio de Janeiro
1978–1982
Medical Intern
1981–1982

Research

Chemotherapy plus local treatment in the management of intraocular retinoblastoma
Archives of Ophthalmology · 1996 · 345 citations
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
The Lancet Oncology · 2017 · 328 citations
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group
Journal of Clinical Oncology · 2005 · 323 citations

RM
Rebecka Meyers
27 papers
HK
Howard Katzenstein
23 papers
Carlos Rodriguez-Galindo
17 papers
Elysia Alvarez
17 papers
Milton Finegold
16 papers
Allison O'Neill
15 papers
Dolores Lopez-Terrada
14 papers
Sarangarajan Ranganathan
14 papers
EP
Elizabeth Perlman
13 papers
Jeffrey Dome
13 papers
Gail Tomlinson
12 papers
GT
Greg Tiao
11 papers

Clinical trials

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
Study chair · Completed
Children's Oncology Group
2004
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031